Introduction
Although therapies for malignant tumors including operation, chemotherapy, and radiation therapy have developed remarkably, the complete conquest of malignant tumors has not been achieved yet. In addition, in many cases, patients suffer from side effects of these therapies such as fatigue, anorexia, pyrexia, infection, and suppression of bone marrow. Thus, new anticancer therapies that have more efficacy and fewer side effects are required. The cellular immune response is considered not to work functionally and sufficiently in patients with advanced malignant tumors, and it has been reported that some tumors escape immune surveillance by several mechanisms. 1 To overcome immune suppression or immune escape in patients with advanced malignant tumors, many biologic therapies that aim at inducing potent antitumor immune responses have been tried.
Dendritic cells (DCs) are potent antigen-presenting cells that can elicit primary and secondary immune responses to foreign antigens. 2, 3 Immature DCs express low levels of major histocompatibility complex (MHC) class I, class II, and costimulatory molecules (CD80, 86) that play important roles in T cell stimulation. 4 When immature DCs capture and take up antigens, DCs downregulate the function of antigen acquisition, but upregulate MHC and costimulatory molecules. As DCs mature, they will express higher levels of MHC and costimulatory molecules and present antigens to antigenspecific T cells and induce immune responses. [4] [5] [6] [7] [8] Since DCs are playing a crucial role in controlling immunity, the use of DCs may be ideal for cancer therapy. 4 Recently, various DC-based therapies have been tried to elicit antitumor responses, 6, [8] [9] [10] [11] [12] [13] [14] [15] and DCs have been used for therapy in patients with some malignant tumors such as malignant melanoma, lymphoma, renal cell carcinoma, pancreatic, and gastric cancer. 16 Interferon (IFN)-a has been used to treat patients with not only viral infections such as hepatitis B and C but also some malignant tumors such as melanoma, renal cell carcinoma, and leukemia. The effects of type I IFN include antiviral function, enhancement of IFN-a/b production, 17, 18 and inhibition of cell growth and angiogenesis. 19 In addition, IFN-a plays a crucial role in the immune system. IFN-a upregulates the expression of MHC class I on the cell surface and enhances the proliferation of Th1-lymphocytes. 20 Previous studies emphasized the importance of IFN-a for the generation of cytotoxic T lymphocytes (CTLs) in specific antitumor immune responses. 21, 22 In addition, we reported previously that IFN-a transduction of poorly immunogenic tumor cells reduces tumorigenicity and leads to a longlasting tumor immunity, 23 and that IFN-a-expressing tumor cells promote the survival of tumor-specific CTLs by preventing apoptosis. 24 IFN-a has been reported to induce the maturation of DCs. Santini et al. 25 demonstrated that IFN-a upregulated the expression of costimulatory molecules (CD80, 86) and MHC class II (HLA-DR) and induced CD83 expression, which is considered to be a marker of mature and activated human DCs. Then, they showed that DCs gained a greater capability to stimulate the proliferation of allogeneic lymphocytes in the presence of IFN-a. 25 Others have also reported the effects of IFN-a on enhancement of DC maturation. 26, 27 However, it has also been reported that IFN-a fails to induce DC maturation, and that the presence of IFN-a prior to or during the differentiation of DCs from the monocyte precursors alters their response to maturation stimuli in the human system. 28 In our previous studies, we demonstrated that IFN-a gene therapy in combination with CD80 transduction reduces tumorigenicity and the growth of established tumors in poorly immunogenic tumor models, 23 and that IFN-a has additive effects on suppressing tumor growth in cooperation with interleukin (IL)-12.
29 Costimulatory molecules such as CD80 are highly expressed on the surface of DCs, and IL-12 is produced mainly by DCs. Therefore, the combined use of DC-based immunotherapy with IFN-a gene therapy is considered reasonable. Recently, Tsugawa et al. 30 reported that combined use of DC with adenoviral vector encoding IFN-a elicits antitumor response in a murine intracranial gliomas model. In this study, as a preliminary investigation of the combined therapy, we investigated the effects of bone marrow-derived DCs and IFN-a-expressing colorectal cancer cells on the proliferation of allogeneic splenocytes. Then, we examined whether DCs and IFN-a-expressing tumor cells display synergistic effects on the induction of antitumor immunity in a therapeutic model to evaluate the possibility of applying this combined therapy to clinical trial.
Results

IFN-a gene transduction does not affect growth of tumor cells in vitro
Each of the tumor cells (wild type (WT), neomycinresistance gene-transduced MC38 (MC38-Neo)-, murine IFN-a-overexpressing MC38 cells (MC38-IFN-a)) with or without g-irradiation were seeded at 5 Â 10 5 cells/well in six-well plates, and enumerated every day in duplicate to compare the growth in vitro of the genetically modified MC38 cells. The growth rates did not differ significantly between MC38-WT, MC38-Neo, and MC38-IFN-a cells within 72 h incubation (data not shown). Cell counts of each tumor cell were decreased to approximately onethird 48 h after 100 Gy g-irradiation.
When nonirradiated tumor cells were incubated with DCs, cell growth of each tumor cell line was almost the same with that of MC38-WT without DCs (data not shown). DCs did not affect the cell growth of tumor cell lines.
With the terminal deoxynucleotidyl transferasemediated dUTP-biotin nick-end labeling assay (TUNEL), we found approximately 50% of the g-irradiated (100 Gy) MC38 cells to be apoptotic 48 h after irradiation (data not shown). The proportion of apoptotic cells after g-irradiation did not differ between the genetically modified MC38 cell lines.
Coincubation with MC38-IFN-a cells does not enhance cytokine production by DCs and phenotypic maturation of DCs
The production of murine IFN-a by modified tumor cells or DCs was confirmed by enzyme-linked immunosorbent assay (ELISA). Nonirradiated MC38-IFN-a cells produced large amounts of IFN-a as shown in Table 1 . On the other hand, 100 Gy g-irradiated MC38-IFN-a cells produced about half as much IFN-a as nonirradiated MC38-IFN-a. There was no difference in IFN-a production between the irradiated MC38-IFN-a cells alone and DCs coincubated with irradiated MC38-IFN-a. IFN-a was not detected in supernatants of MC38-WT cells, MC38-Neo cells, DCs, splenocytes, and DCs with MC38-Neo cells.
IL-1b, IL-12, and TNF-a production by DCs was also confirmed by ELISA. Enhancement of these cytokine production was not observed when DCs were coincubated with parental or genetically modified tumor cells (data not shown). Expression of CD80, CD86, and I-A b molecules on DCs was compared by flow cytometry. Coincubation with genetically modified tumor cells did not enhance the expression of those molecules (data not shown). From these data, coincubation with parental or genetically modified tumor cells does not enhance the cytokine production by DCs as well as the phenotypic maturation of DCs in this system.
Proliferation of allogeneic splenocytes is markedly enhanced by coincubation with MC38-IFN-a cells
To investigate proliferative effects of DCs and MC38-IFN-a cells on allogeneic splenocytes, we performed cell proliferation assays. As shown in Figure 1 , stimulation by both DCs and MC38-IFN-a cells markedly enhanced the proliferation of allogeneic splenocytes compared with stimulation by DCs alone or by DCs and MC38-Neo (P ¼ 0.007 or 0.020, respectively). When exogenous IFN-a was added to the culture of DCs and MC38-Neo cells, the proliferation of allogeneic splenocytes was Figure 2 and Table 2 . All these 12 tumor-free mice rejected the subsequent parental MC38 cell challenge. DCs+MC38-Neo and splenocytes+MC38-IFN-a cells also had preventive effects on the development of parental tumors compared with splenocytes alone, although the preventive effects were less than those of DCs+MC38-IFN-a.
CD8
+ cells and asialo-GM-1 + cells contribute to the antitumor effects induced by DCs and IFN-a-expressing tumor cells
We depleted immune cells using anti-CD4, anti-CD8, and anti-asialo-GM-1 antibodies to explore the mechanism of the antitumor effects induced by DCs and IFN-aexpressing tumor cells. We depleted these immune cells in vivo after inoculation with DCs and IFN-a-expressing tumor cells. Then, MC38-WT cells were injected and the WT tumor development was measured. When CD8 + cells or asialo-GM-1 + cells were depleted, we observed obvious growing WT tumors in those mice, whereas we detected no tumor in mice not depleted of any immune cells (P ¼ 0.015 or 0.023, respectively, Figure 3 ). On the other hand, in CD4 + cell-depleted mice, the antitumor effects induced by DCs and IFN-a-expressing tumor cells were diminished marginally. Thus, DCs and IFN-a therapy seemed to stimulate CD8 + cells and asialo-GM-1 + cells mainly in vivo.
Therapeutic inoculation of DCs and MC38-IFN-a cells suppresses outgrowth of established parental MC38 tumors
We evaluated the therapeutic effects of DCs and MC38-IFN-a on established parental MC38 tumors. As shown (Table 3A) . The CD11c + cells did not seem to be the injected DCs because we detected only a few PKH26-labeled cells infiltrating the tumor tissue 24 h after the inoculation (Table 3B ). There was no difference in the number of PKH26-labeled DCs between the group of mice treated with DCs+MC38-Neo and the group treated with DC+MC38-IFN-a cells. In addition, more NK1.1 + cells were detected in the tumor-infiltrating mononuclear cells of mice treated with the combined therapy (Table 4) . These results suggest that coinjection of DCs and MC38-IFN-a induces potent cellular immune responses, which includes recruitment of the host's own DCs.
Tumor-specific cytolysis was clearly detected when splenocytes of mice inoculated with both DCs and MC38-IFN-a cells were stimulated with MC38-IFN-a in vitro
To investigate the induction of tumor-specific immune responses in mice treated with DCs and MC38-IFN-a in vivo, we stimulated splenocytes of the mice with MC38-IFN-a in vitro because our previous study showed that MC38-IFN-a cells stimulate tumor-specific CTLs in vitro efficiently. 23 As shown in Figure 5 , tumor-specific cytolysis was clearly detected, although splenocytes of naive mice did not display any tumor specificity after in vitro stimulation of MC38-IFN-a cells (data not shown). These results suggest that the combined use of DCs and MC38-IFN-a elicits potent tumor-specific cellular immune responses in vivo.
Discussion
Several experimental therapies utilizing cytokine genetransduced tumor cells have been performed. The local delivery of a high concentration of cytokine, which reduces systemic side effects, is implicated in the benefits of these therapies. IFN-a-expressing tumor cells have advantages in eliciting antitumor immune responses over IFN-a gene-transduced nontumor cells such as fibroblasts, because the expression of MHC molecules on which tumor-associated antigens would exist is upregulated, 29 and thus facilitate the recognition of tumorassociated antigens on MHC molecules of the transduced cells by tumor-specific T cells. However, for clinical use, patients' own tumor tissues are required to make genetically modified tumor cells. Effective transduction system is also needed to establish modified cells, which produce a large amount of the target cytokine.
DCs have been used widely for biologic therapy in cancer because of their physiologic roles in initiating and modulating the host's immune response. For therapeutic use, DCs are usually pulsed with tumor-associated antigen by incubating them with synthetic peptides corresponding to a known epitope, tumor lysate, or apoptotic tumor cells. A fusion technique to make hybrids of DCs and tumor cells is also performed for DC-based cancer therapy. In some trials, DC-based therapies resulted in better clinical courses compared with conventional therapies, such as chemotherapy and/or radiation therapy, without any severe side effects even in patients with advanced malignant tumors.
Induction of potent, long-lasting tumor-specific responses is crucial for preventing tumor enlargement and maintaining a tumor-free state. Both DC-based immunotherapy and IFN-a therapy have been widely evaluated, and antitumor effects induced by each 31 reported that IFN-a-transfected DC showed marked antitumor effects against central nervous system tumors. Since IFN-a therapy is supposed to have additive or synergistic antitumor effects in cooperation with DC therapy, we investigated the efficacy of the combined therapy of bone marrow-derived DCs and IFN-a-expressing tumor cells in the present study.
When exogenous IFN-a was added to the culture of DCs and MC38-Neo cells, the proliferation of allogeneic splenocytes was significantly suppressed compared with the stimulation by DCs and MC38-IFN-a cells (Figure 1) . In this experiment, we added 10 ng of IFN-a in the DC and MC38-Neo culture at the beginning of cultivation because the same number of MC38-IFN-a cells produces approximately total 10 ng of IFN-a for 48 h. Since it has been reported that IFN-a has suppressive effects on cell proliferation, 10 ng of IFN-a might be too much to observe proliferation of the allogeneic splenocytes. We observed less antiproliferative effects of IFN-a at the concentration of 1 ng. Furthermore, we could not observe DC maturation by coincubation with MC38-IFN-a cells. Thus, we hypothesize that continuous supply of small amount of IFN-a might be effective on the proliferation of allogeneic splenocytes. We are planning to use IFN-aexpressing fibroblasts instead of MC38-IFN-a cells to evaluate this hypothesis.
DCs coinjected with MC38-IFN-a cells prevented the development of parental tumors effectively in mouse model experiments. Therapeutic injection of DCs with MC38-IFN-a cells also suppressed the outgrowth of established parental tumors. Although IFN-a has a suppressive effect on cell growth, the proliferation of MC38-IFN-a cells was almost the same as that of the parental tumor cells. Cell numbers (survival) and the proportion of apoptotic cells among MC38-IFN-a cells after g-irradiation were almost the same as those of MC38-WT or MC38-Neo cells. Thus, IFN-a gene transduction did not affect the growth, viability, or sensitivity to g-irradiation of the MC38 cells in vitro in this model. Furthermore, our previous data suggest that an antiangiogenic effect is not induced by inoculation of IFN-aexpressing MC38. 29 Therefore, antitumor effects induced by coinjection of DCs and IFN-a-expressing tumor cells in this study are thought to be due to the host's immune responses. These interpretations are supported by the immunohistologic analysis, experiments in mice depleted the individual immune cells, and investigation of cytolytic activity using splenocytes of mice treated with the combined therapy. These experiments showed that CD8 + cells and asialo-GM-1 + cells contributed to the antitumor effects induced by DC and IFN-a therapy, and host's DCs also seem to be involved in the effects.
In the present study, we inoculated therapeutically DCs admixed with MC38 cells, but not DCs preincubated with MC38 cells in vitro before injection, because a simple procedure is better for clinical use. In addition, since we lost many DCs after in vitro cultivation, and we could not recover enough DCs to use for the therapy. We thought it better to avoid loosing DCs, as it is often difficult to obtain many DCs from patients with advanced malignant tumors.
In general, as a live tumor vaccine may lead to the establishment of new tumors and metastases, it may be difficult to use in a clinical study. However, we tried to perform therapeutic inoculation of live MC38-IFN-a cells because almost all mice inoculated with these cells were free of tumors in our previous study. 29 We demonstrated the preferable effects of nonirradiated to g-irradiated MC38-IFN-a cells on established tumors. The difference of antitumor effects between g-irradiated and nonirradiated MC38-IFN-a cells might be due to the amount of IFN-a secreted by these genetically modified tumor cells after injection. Now, we are trying to establish new MC38 cell lines, which produce less IFN-a to compare the antitumor effects of the MC38-IFN-a used in this study.
To promote immune responses in vivo, DCs capture antigens at peripheral tissues, and then migrate to lymph nodes where T cells are activated and stimulated by mature DCs presenting tumor-associated antigens. In a previous study, some DCs migrated from the tumor site to draining lymph nodes within 24 h after inoculation. 32 The expression of CC chemokine receptor-7 on the DCs may be upregulated by coincubation with apoptotic tumor cells as reported previously, 33 facilitating the migration to lymph nodes. As we observed that few DCs infiltrated the tumor tissue 24 h after the inoculation, the inoculated DCs would have migrated into draining lymph nodes. However, we could find only a few tiny swollen lymph nodes in mice treated with coinjection of DCs and genetically modified tumor cells in the present study, and could not prove the migration Although the combined use of DCs and IFN-aexpressing tumor cells reduced parental tumor growth significantly, we did not observe any eradication of established parental tumors using this therapy. More effective modifications of the therapy, such as the administration of immunoadjuvants, or other cytokines may be necessary before clinical use for patients with immunesuppression. A new therapy to use DCs, irradiated MC38-WT cells and IFN-a-expressing fibroblasts is under investigation in our laboratory. From our results, immunotherapy by combined use of DCs and IFN-a may be a candidate for clinical cancer therapy, although further investigation is needed to augment the effectiveness.
Materials and methods
Mice
Female C57BL/6 (B6) and BALB/c mice 6 to 8 weeks old were purchased from Sankyo Lab Service (Tokyo, Japan) for use in experiments at ages from 8 to 12 weeks. Mice were maintained in an animal care facility at Showa University. This study has been approved by the Ethical Committee for Animal Experiments of Showa University.
Cell lines, culture medium, and reagents
The MC38 murine colorectal adenocarcinoma cell line (B6 mouse origin) and the YAC-1 lymphoma cell line were maintained in RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf serum, 2 mM L-glutamine, 100 IU/ml penicillin, 100 mg/ml streptomycin, 10 mM HEPES buffer, 1 mM minimum essential medium sodium pyruvate, and 0.1 mM minimum essential medium nonessential amino acids (complete medium, CM) in a humidified incubator with 5% CO 2 in air at 371C. All cell culture reagents were purchased from Life Technologies (Gaithersburg, MD, USA).
Retroviral transduction and genetically modified tumor cell lines
Tumor cells were transduced using retroviral vectors according to standard protocols 34 and selected for antibiotic resistance in culture medium containing 0.5 mg/ml. G418 (Sigma, St Louis, MO, USA). The MC38 cell line genetically modified to produce IFN-a (MC38-IFN-a) was established as described previously. 23 Expression of murine IFN-a was confirmed by ELISA using a commercially available kit according to the manufacturer's instructions (mouse IFN-a ELISA, PBL Biomedical Laboratories, New Brunswick, NJ, USA). MC38 cells expressing the neomycin-resistance gene following retroviral transduction with MFG-Neo (MC38-Neo) were used as control cells. 23 Characterization of g-irradiated tumor cells g-Irradiation (100 Gy) was performed with Gammacell 3000 Elan (Nordion International Inc., Kanata, Canada). After irradiation, MC38-IFN-a cells (5 Â 10 5 cells) were incubated in CM in six-well plates, and were enumerated every day in duplicate. Cell numbers in each well were determined microscopically. To detect the apoptosis of tumor cells induced by g-irradiation, TUNEL was performed using an APO-DIRECTt Kit (Pharmingen, San Diego, CA, USA). To determine the changes of IFN-a production with g-irradiation, the culture supernatant of 1 Â 10 5 irradiated tumor cells was examined using the IFN-a ELISA 48 h after g-irradiation.
Phenotypic change of DCs and cytokine production by DCs after coincubation with MC38-IFN-a
To evaluate DC maturation induced by coincubation with MC38-IFN-a, expression of surface molecules on DCs were examined using fluorscein isothiocyanate (FITC)-conjugated anti-I-A b CD80, and CD86 monoclonal antibody (Pharmingen). Furthermore, cytokine production by DCs was detected by ELISA using a commercially available kit according to the manufacturer's instructions (mouse IFN-a ELISA obtained from PBL Biomedical Laboratories, and Endogen mouse IL-1b ELISA, mouse IL-12p70 ELISA, and mouse TNF-a ELISA obtained from Pierce Biotechnology Inc., Rockford, IL, USA).
Preparation and purification of DCs
DCs were generated as reported previously with some modification. 35 In brief, bone marrow cells were obtained from the femurs and tibias of B6 mice. After treatment to lyse erythrocytes, the bone marrow cells were depleted of B-and T-lymphocytes with anti-B220 (RA3-3A1/6.1, TIB-146; American Type Culture Collection (ATCC), Manassas, VA, USA), anti-CD4 (GK1.5, TIB207; ATCC), and anti-CD8 antibodies (2.43, TIB210; ATCC) for 1 h on ice, followed by a 30-min incubation with rabbit compliment (obtained from Cedarlane, Hornby, Canada). The recovered cells were put in six-well plates in 4 ml of CM at a concentration of 1 Â 10 6 cells/ml and incubated overnight in 5% CO 2 in air at 371C. After overnight incubation, nonadherent cells were harvested, and put into flasks in CM containing 50 ng/ml each of murine GM-CSF and IL-4 (both were obtained from Pepro Tech EC, London, UK) at a concentration of 1.5 Â 10 5 cells/ml. After 7 days, nonadherent cells were harvested, and were centrifuged at 200 g for 10 min. The cells were washed with Hank's balanced salt solution (HBSS; Life Technologies) supplemented with 0.5% BSA, and then were incubated with anti-CD11c (N418)-magnetic beads and passed through a positive selection column (Type MS+) in a magnetic field (MACS; Miltenyi biotec, Bergisch Gladbach, Germany). After rinsing, the column was removed from the magnetic field, and CD11c + cells were eluted from the column and washed with HBSS before use. The cells were 80-90% CD11c positive after selection with the MACS system. 
Antitumor effects of DCs and MC38-IFN-a cells in immune cell-depleted mice
To determine the role of the immune system in the reduction of in vivo tumor growth in the establishment model, CD4 + T cells, CD8 + T cells, or asialo-GM-1 + cells were depleted by an antibody method as we performed previously. 29 Culture medium from hybridomas producing the following antibodies was used at appropriate dilutions/concentrations: anti-CD4 (GK1.5, TIB207; ATCC) and anti-CD8 (2.43, TIB210; ATCC). For depletion of asialo-GM-1 + cells, anti-asialo-GM-1 was obtained from WAKO (Osaka, Japan). All antibody doses and treatment regimens were determined in preliminary studies using the same lots of antibody employed for the experiments. Treatment was confirmed to delete completely the desired cell population for the entire duration of the study, as determined by flow cytometric analysis (data not shown). After DCs and MC38-IFN-a cells were inoculated i.p. twice at a 7-day interval (days À14 and À7), we depleted CD4 + T cells, CD8 + T cells, or asialo-GM-1 + cells (days À5, À4, and À3). At 1 week after the vaccination (day 0), the mice were injected s.c. with 1 Â 10 5 MC38-WT cells in the right flank. Each experiment involved five mice per group. Tumor size was measured twice a week using vernier calipers. Tumor tissues were harvested 3 days after the last inoculation (17 days after WT inoculation), and were immediately embedded in optimal clotting temperature (OCT) compound (Tissue Tek, Elkhart, IN, USA) and frozen. Serial 5-mm sections were exposed to anti-CD4, CD8a, and CD11c antibody (Nippon Becton Dickinson, Tokyo, Japan). Rat IgG2a (Nippon Becton Dickinson) was used as a control antibody. Immunostaining was completed with a Vectastain ABC kit (Vector, Burlingame, CA, USA). Immunoreactive cells were counted in 10 fields using a light microscopy ( Â 400) in a blinded manner. To observe the localization of the injected DCs in the established tumors of mice that received the combined therapy, DCs were labeled with a fluorescent dye using a PKH26 red fluorescent cell linker kit (obtained from Sigma-Aldrich Japan, Tokyo, Japan). After labeling, DCs were inoculated around the established tumor. Tumor tissues were harvested 1 day or 3 days after the DC inoculation, and the labeled DCs in the tumor tissue were enumerated under a fluorescence microscope. Each experiment involved two mice per group. DCs and 1 Â 10 5 MC38-IFN-a on days 0 and 7, and a subsequent injection of MC38-WT (1 Â 10 5 cells) on day 14, were reinjected with 3 Â 10 5 MC38-WT on day 50. After 2 weeks, splenocytes were harvested and, 2 Â 10 6 splenocytes were incubated with g-irradiated MC38-IFNa cells (100 Gy, 2 Â 10 5 cells/ml) in 24-well plates. After 7 days, responder cells (1 Â 10 6 cells/ml) were restimulated with irradiated MC38-IFN-a cells (100 Gy, 1 Â 10 5 cells/ ml) and irradiated syngeneic naive splenocytes (30 Gy, 1 Â 10 6 cells/ml) in the presence of 50 IU/ml of recombinant mouse IL-2 (Becton Dickinson). Cytolytic assays were performed 7 days after the last stimulation using the responder cells as effector cells. ) and various numbers of effector cells at indicated effector to target ratios (E:T) were plated in 200 ml of CM in each well of the 96-well roundbottomed plates.
51
Cr-release was measured after a 4-h incubation at 371C. Percent lysis was determined using the formula: (release in assayÀspontaneous release) Â 100/(maximum releaseÀspontaneous release). Maximum release was determined by lysis of labeled target cells with 1% Triton X-100. Spontaneous release was measured by incubating target cells in the absence of effector cells, and was less than 15% of maximum release.
Statistical analyses
Significance was assessed with Student's t-test or Wilcoxon's analysis. Differences between groups were considered significant when the P-value was lower than 0.05.
Abbreviations DC, dendritic cell; IFN, interferon; MC38-IFN-a, IFN-aoverexpressing MC38; MC38-Neo, neomycin-resistance gene-transduced MC38; MC38-WT, MC38 wild type; MHC, major histocompatibility complex; CTL, cytotoxic T-lymphocytes; IL, interleukin; B6, C57BL/6; CM, complete medium; ELISA, enzyme-linked immunosorbent assay; TUNEL, terminal deoxynucleotidyl transferasemediated dUTP-biotin nick-end labeling assay; ATCC, American Type Culture Collection; HBSS, Hank's balanced salt solution; FITC, fluorescein isothiocyanate; OCT, optimal clotting temperature; E:T, effector to target ratio.
